Skip to main content
. Author manuscript; available in PMC: 2017 Jul 18.
Published in final edited form as: Pediatr Res. 2017 Jan 18;81(6):865–872. doi: 10.1038/pr.2017.15

Table 3.

Erythropoietin exposure in neonates with HIE receiving hypothermia after high-dose Epo

Phase I
500 U/kg (n=6)		 Phase I
1000 U/kg (n=7)		 Phase I
2500 U/kg (n=8)		 Phase II
1000 U/kg (n=23)
Dose Frequency every 48 h every 48 h every 48 h every 24 h × 3 doses then every 48h
Cmax after 1st Dose (mU/ml) 6,844 (6,596–7,705) 13,851 (11,613–16,798) 30,691a (27,493–40,677) 12,730 (10,609–15,574)
AUC48h (mU*h/ml) 48,280 (46,180–55,071) 114,180 (102,850–120,650) 266,260 (246,310–274,250) 191,300 (177,510–209,160)
AUC7d (mU*h/ml) 210,950b (190,840–239,050) 483,830c (426,120–510,560) 1,107,500 (1,007,600–1,145,800) 541,610 (491,850–599,010)

All data are median (IQR); Cmax, maximum observed concentration after the first dose; AUC48h, area under the plasma concentration-time curve during the first 48 hours of dosing; AUC7d, cumulative area under the plasma concentration-time curve during the first 7 days of dosing.

a

n=7 as one patient did not have a concentration measured in first 6 hours after the dose.

b

n=4 as two patients received ≤ 3 doses.

c

n=6 as one patients received only 3 doses.